Branch2 Intelligence
SCHEDULE 13G/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
Key takeaway
Adial Pharmaceuticals filed a Schedule 13G/A, signaling a passive significant shareholder adjustment.
- Step 11st-order: Adial Pharmaceuticals files Schedule 13G/A with SEC, disclosing passive shareholder ownership change.
- Step 22nd-order: No material operational or financial change; the filing is a routine disclosure with negligible market impact.
Source: SEC EDGAR — Current filings
This is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch2 is not authorised or regulated. Do your own research.